OPU
STLN

Omni Partners US’s Starling Oncology STLN Stock Holding History

Omni Partners US’s Portfolio STLN Stock Details STLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$7.65M Buy
769,766
+700,667
+1,014% +$6.96M 0.39% 43
2021
Q2 		$688K Buy
+69,099
New +$696K 0.03% 191

Other funds holding STLN

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
DKCM
Davidson Kempner Capital Management New York $8.42B AUM 61.81% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.26B AUM 81.38% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.04B AUM 31.03% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return

Omni Partners US's STLN Position: Q3 2021 in Review

Omni Partners US increased its Starling Oncology (STLN) stake by 1,014% in Q3 2021, buying an estimated $6.96M and bringing the position to 769,766 shares worth $7.65M. The position accounts for 0.39% of the portfolio, ranked #43.

Omni Partners US first reported a position in STLN in Q2 2021 and has held it in 2 quarters since. 51 funds tracked by Wall St. Rank hold STLN as of Q3 2021.

  • Omni Partners US held 769,766 shares of Starling Oncology worth $7.65M as of Q3 2021.
  • Omni Partners US bought 700,667 Starling Oncology shares in Q3 2021, an estimated $6.96M.
  • Starling Oncology made up 0.39% of Omni Partners US's portfolio in Q3 2021, its #43 holding.
  • Omni Partners US first reported a position in Starling Oncology in Q2 2021 and has held it in 2 quarters since.
  • 51 funds tracked by Wall St. Rank held Starling Oncology as of Q3 2021.

Based on Omni Partners US's 13F filing for Q3 2021, filed 15 Nov 2021.